Klin Farmakol Farm. 2009;23(2):64-70

Contemporary view on antiarrhythmic drugs

doc. MUDr. Petr Heinc Ph.D
I. interní klinika FN a LF UP Olomouc

There is evidence of good antiarrhythmic effect of available drugs for arrhythmia treatment but these drugs have no significant effect

on mortality and all of them have some proarrhythmic effect. Radiofrequency ablation became the treatment method of the 1st. choice

in patients with supraventricular tachyarrhythmias of reentry mechanism and in patients with ventricular tachyarrhythmias without

structural heart disease presentation. Antiarrhythmic drug therapy is the treatment of the 2nd choice in these cases. Antiarrhythmic

drug therapy is the treatment of the1st choice in patients with complex supraventricular and ventricular tachyarrhythmias and plays the

strategic role in hybrid therapy in combination with radiofrequency ablation or cardioverter-defibrilator implantation. The relationship

between and the results of pharmacologic and nonpharmacologic studies are considered. Pharmacokinetic mechanisms and clinical

effects of class IC and III antiarrhythmic drugs are described.

Keywords: class I and III antiarrhythmic drugs, proarrhythmia, mortality, nonpharmacologic treatment of arrhythmia.

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Heinc P. Contemporary view on antiarrhythmic drugs. Klin Farmakol Farm. 2009;23(2):64-70.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006; 354: 934-941. Go to original source... Go to PubMed...
    2. Hsu L, Jais P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004; 351: 2373-2383. Go to original source... Go to PubMed...
    3. Gentlesk P, Sauer W, Gerstenfeld E, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007; 18: 9-14. Go to original source... Go to PubMed...
    4. Zado E, Callans D, Riley M, et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly. J Cardiovasc Electrophysiol. 2008; 19: 621-626. Go to original source... Go to PubMed...
    5. Corley SD, Epstein AE, DiMarco JP, et al. AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004; 109: 1509-1513. Go to original source... Go to PubMed...
    6. Beyerbach D, Zipes D. Mortality as an endpoint in atrial fibrillation. Heart Rhythm. 2004; 1(2 Suppl) B8-B18. Go to original source... Go to PubMed...
    7. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and European Heart Rhythm Association. Europace 2007; 9: 1006-1023. Go to original source... Go to PubMed...
    8. Anderson J. Acute treatment of atrial fibrillation and flutter. J Am Coll Cardiol 1996; 17: 17-21. Go to original source... Go to PubMed...
    9. Waldo A, Prystowsky EN. Drug treatment of atrial fibrillation in the managed era. Am J Cardiol 1998; 81: 23C-29C. Go to original source... Go to PubMed...
    10. Podrid PJ. Amiodarone: Reevaluation of an old drug. Ann Int Med 1995; 122: 689-700. Go to original source... Go to PubMed...
    11. Pratt CM, Singh SN, Al Khalidi HR, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2004; 43: 1211-1216. Go to original source... Go to PubMed...
    12. Kober L, Torp-Pedersen CH, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-2687. Go to original source... Go to PubMed...
    13. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1991; 12: 1112-1131. Go to original source...
    14. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Circulation 1990; 81: 686-690. Go to original source... Go to PubMed...
    15. Antzelevith C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. J Am Coll Cardiol 1994; 23: 259-277. Go to original source... Go to PubMed...
    16. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent: Specific block of rapidly activating delayed rectifier K current by dofetilide. Circ Res 1993; 72: 75-83. Go to original source... Go to PubMed...
    17. Wang Z, Fermini B, Nattel S. Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res 1993; 73: 276-285. Go to original source... Go to PubMed...
    18. Wijffels MC, Crijns HJ. Recent advances in drug therapy for atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14: S40-S47. Go to original source... Go to PubMed...
    19. Tamargo J, Caballero R, Gomez R, et al. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004; 62: 9-33. Go to original source... Go to PubMed...
    20. Varro A, Biliczki P, Iost N, et al. Theoretical possibilities for the development of nove antiarrhythmic drugs. Curr Med Chem 2004; 11: 1-11. Go to original source... Go to PubMed...
    21. Antman EM, Beamer AD, Cantillon C, et al. Therapy of refractory symptomatic atrial fibrillation and flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698. Go to original source... Go to PubMed...
    22. Geller JC, Geller M, Carlson MD, Waldo AL. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Am J Cardiol 2001; 87: 172. Go to original source... Go to PubMed...
    23. Meinertz T, Lip GY, Lombardi F, et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002; 90: 1300. Go to original source... Go to PubMed...
    24. Pritchett EL, Page RL, Carlson M, et al. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003; 92: 941. Go to original source... Go to PubMed...
    25. Chimienti M, Cullen MT, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the flecainide and propafenone Italian Study Investigators. Am J Cardiol 1996; 77: 60A. Go to original source... Go to PubMed...
    26. Aliot E, Denjoy I, Atuel et al. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996; 77: 66A. Go to original source... Go to PubMed...
    27. Zarembski DG, Nolan PE Jr, Slack MK, et al. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155: 1885. Go to original source...
    28. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781. Go to original source... Go to PubMed...
    29. Podrid PJ, Anderson JL. Safety and tolerability of longterm propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group. Am J Cardiol 1996; 78: 430. Go to original source... Go to PubMed...
    30. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913. Go to original source... Go to PubMed...
    31. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861. Go to original source... Go to PubMed...
    32. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42: 20.
    33. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007; 356: 935. Go to original source... Go to PubMed...
    34. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997; 350: 1417.
    35. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225. Go to original source... Go to PubMed...
    36. Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57: 124. Go to original source... Go to PubMed...
    37. Horowitz LN, Spielman SR, Greenspan AM, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6: 1402. Go to original source... Go to PubMed...
    38. Winters SL, Kukin M, Pe E, et al. Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. Am J Cardiol 1993; 72: 38A-43A. Go to original source... Go to PubMed...
    39. Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter; A multicenter, randomized, doubleblind, placebo controlled study. Sotalol Multicenter Study Group. Am Heart J 1995; 129: 739-748. Go to original source... Go to PubMed...
    40. Vos MA, Golitsin SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and fibrillation. Heart 1998; 79: 568-573. Go to original source... Go to PubMed...
    41. Poelzl G, Kratzer H, Ebner A, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81: 1450-1454. Go to original source... Go to PubMed...
    42. Demolis GM, Funck-Brentano C, Ropers JR, et al. Influence of dofetilide on QT interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94: 1592-1599. Go to original source... Go to PubMed...
    43. Kowey PR, Marinchack RA, Rials SJ, et al. Pharmacologic and pharmacokinetic profile of the class 3 antiarrhythmic drugs. Am J Cardiol 1997; 80: 16G-23G. Go to original source... Go to PubMed...
    44. Nademanee K, Bailey WM, O'Neill G, et al. Electrophysiologic and hemodynamic effects of dofetilide in patients with depressed ventricular function: A randomized, double-blind, placebo-controlled study. PACE 1998; 21: 867.
    45. Campbell T, Greenbaum RA, Channer KS, et al. Mortality in patients with atrial fibrillation-1 year follow up of EMERALD (European and Australian Multicenter Evaluation Research of Atrial Fibrillation Dofetilide). J Am Coll Cardiol 2000; 35(Suppl. A): 154.
    46. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter. The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385. Go to original source... Go to PubMed...
    47. Norgaard BL, Watchell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Am Heart J 1999; 137: 1062-1069. Go to original source... Go to PubMed...
    48. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular functions. A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 2001; 104: 292-295. Go to original source... Go to PubMed...
    49. Lee KS. Ibutilide, a new compound with potent class 3 antiarrhythmic activity, activates a slow inward Na current in guinea pig ventricular cells. J Pharmacol Exp Ther 1998; 286: 99-108. Go to PubMed...
    50. Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidlyactivating delayed rectifier K current (I, U) in AT-1 cells. Circulation 1995; 91: 216-221. Go to original source... Go to PubMed...
    51. Murray KT. Ibutilide. Circulation 1998; 97: 493-497. Go to original source... Go to PubMed...
    52. Volgman AS, Carberry PA, Stambler BS. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998; 31: 1414-1419. Go to original source... Go to PubMed...
    53. Tai ChT, Chen SA, Feng AN, et al. Electropharmacologic effect of class I and class III antiarrhythmia drugs on typical atrial flutter. Circulation 1998; 97: 1935-1945. Go to original source... Go to PubMed...
    54. Oral K, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340: 1849-1854. Go to original source... Go to PubMed...
    55. Kowey PR, VanderLugt JR, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute cardioversion of atrial fibrillation/flutter. Am J Cardiol 1996; 78: 46-52. Go to original source... Go to PubMed...
    56. Pritchett EL, Page RL, Connolly SJ, et al. Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J Am Coll Cardiol 2000; 36: 794-802. Go to original source... Go to PubMed...
    57. Connolly SJ, Schnell DJ, Page RL, et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 2001; 88: 974-979. Go to original source... Go to PubMed...
    58. Connolly SJ, Schnell DJ, Page RL, et al. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. Am Heart J 2003; 146: 489-493. Go to original source... Go to PubMed...
    59. Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in patients after a recent myocardial infarction: A randomized, placebocontrolled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109: 990-996. Go to original source... Go to PubMed...
    60. Manning AS, Bruyninckx C, Ramboux J, et al. SR 33589, a new amiodarone-like agent: Effect on ischemia and reperfusion-induced arrhythmias in anesthesized rats. J Cardiovasc Pharmacol 1995; 26: 453-461. Go to original source... Go to PubMed...
    61. Sun W, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999; 100: 2276-2281. Go to original source... Go to PubMed...
    62. Verdvin SC, Vos MA, Leunissen HDM, et al. Evaluation of the acute electrophysiologic effect of intravenous dronedarone, an amiodaron-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. J. Cardiovasc Pharmacol 1999; 33: 212-222. Go to original source... Go to PubMed...
    63. Gautier P, Guillemare E, Marion A, et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 2003; 41: 191-202. Go to original source... Go to PubMed...
    64. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone of cardiovascular events in atrial fibrillation. N Engl J Med 2009; 359: 668-678. Go to original source... Go to PubMed...
    65. Singh BN, Connoly SJ, Crijns HJGM, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357: 987-999. Go to original source... Go to PubMed...
    66. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839. Go to original source... Go to PubMed...
    67. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343-1345. Go to original source... Go to PubMed...
    68. Michell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? J Am Coll Cardiol 2003; 42: 81-87. Go to original source... Go to PubMed...
    69. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39-III43. Go to original source... Go to PubMed...
    70. Pratt CM, Ruskin JN, Friedrieck T. Dofetilide use in atrial fibrillation: A treatment strategy to minimize proarrhythmic risk. (abstract) J Am Coll Cardiol 2000; 35(Suppl. A), 154A.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.